Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $230,848.54 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 2,561 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $90.14, for a total value of $230,848.54. Following the completion of the transaction, the executive vice president directly owned 29,276 shares in the company, valued at approximately $2,638,938.64. This represents a 8.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total value of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total value of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.54, for a total transaction of $9,118,555.02.

Dianthus Therapeutics Stock Up 3.6%

Shares of Dianthus Therapeutics stock traded up $3.18 during trading on Thursday, reaching $92.48. The company’s stock had a trading volume of 921,016 shares, compared to its average volume of 931,449. The business’s 50-day moving average price is $89.05 and its 200-day moving average price is $86.15. The firm has a market cap of $5.21 billion, a PE ratio of -23.18 and a beta of 1.47. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Walleye Capital LLC bought a new stake in shares of Dianthus Therapeutics during the second quarter worth about $1,743,000. SummitTX Capital L.P. increased its stake in shares of Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock valued at $8,396,000 after buying an additional 12,118 shares during the period. California State Teachers Retirement System increased its stake in shares of Dianthus Therapeutics by 155.5% in the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after buying an additional 24,697 shares during the period. Bank of America Corp DE bought a new position in Dianthus Therapeutics in the 2nd quarter valued at approximately $25,036,000. Finally, Spruce Street Capital LP bought a new position in Dianthus Therapeutics in the 2nd quarter valued at approximately $34,587,464. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Wedbush upped their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. initiated coverage on Dianthus Therapeutics in a research report on Friday, September 11th. They issued an “overweight” rating and a $135.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $158.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Roth Capital began coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 27th. They set a “buy” rating and a $113.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $128.77.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.